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Objective: There is no clinical evidence that supports the beneﬁt of integrative medicine, deﬁned as
combination therapy of oriental and western medicine, on obesity-related hypertension. This study
evaluates the efﬁcacy of Bofu-tsusho-san (BOF), an oriental herbal medicine, on the ambulatory blood
pressure (BP) proﬁle in hypertensive patients with obesity.
Methods: The study design was a multicenter, randomized, open-label, parallel-group controlled trial in
107 hypertensive patients with obesity. Participants were randomly assigned to receive either the con-
ventional control therapy or BOF add-on therapy. In both groups antihypertensive therapy was aimed at
achieving the target clinic BP. The primary outcome was change in the ambulatory BP proﬁle from
baseline to 24 weeks after randomization.
Results: Daytime systolic BP variability, an important parameter of ambulatory BP proﬁle, was decreased
in the BOF group, and the difference in the changes in daytime systolic BP variability was signiﬁcant
between the BOF and control group (Control vs BOF; the change from baseline in daytime systolic BP
variability, 1.0 ± 3.3 vs 1.0 ± 3.3%; p ¼ 0.006).
Conclusion: The BOF add-on therapy effectively improved the ambulatory BP variability. This is the ﬁrst
report suggesting that an integrative medicine approach may exert favorable effects on obesity-related
hypertension compared with conventional pharmaceutical treatment.
Clinical trial registration: UMIN000003878.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Obesity-related disease patients are increasing and obesity is aience and Cardiorenal Medi-
of Medicine, 3-9 Fukuura,
(K. Tamura).
Ireland Ltd. This is an open accessmajor medical problem associated with the development of hy-
pertension, type 2 diabetes (T2DM) and dyslipidemia, and ulti-
mately life-threatening cardiovascular disease (CVD) [1]. Obesity is
reportedly often accompanied by hypertension and obesity-related
hypertension is closely associated with the development of sys-
temic atherosclerosis along with T2DM and dyslipidemia, resulting
in increased CVD morbidity [2]. Therefore, there is a need for new
treatment strategies for the management of both obesity andarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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a variety of anti-obesity drugs and procedures, such as bariatric
surgery, have been developed as treatments under the approach of
western medicine that have helped a number of severely obese
patients, but these treatment modalities are limited due to both
adverse effects and the degree of invasiveness [3,4].
Bofu-tsusho-san (BOF), an oriental herbal medicine, has been
used for obese patients in Japan. BOF, composed of 18 crude herbal
drugs (Supplemental Table 1), has been reported to exert various
anti-obesity effects by stimulating adipose tissue in rodents [5,6].
With respect to active ingredients of BOF, a previous study re-
ported that main effective components of BOF were shizonepetae
spica, glycyrrhizae radix, forsythiae fructus and ephedra herba.
Ephedrine contained in ephedra herba acts on sympathetic nerve
terminal and promotes the release of norepinephrine. Increased
norepinephrine stimulates b-receptor in adipose tissue, and in-
duces thermogenesis in brown adipose tissue and lipolysis in
white adipose tissue through increases the synthesis of cAMP.
Additionally, since glycyrrhizae radix, forsythiae fructus and schiz-
onepetae spica have a potent inhibiting effect of phosphodies-
terase, degradation of cAMP is inhibited to exert more powerful
anti-obesity effect described above [5]. In addition, we recently
reported that BOF exerted a favorable effect on metabolism,
including an antihypertensive effect, not only via its beneﬁcial
effect on adipose tissue function, but also its appetite inhibitory
effect in a mouse model of human metabolic disorders with
obesity [7]. The development of highly efﬁcient antihypertensive
drugs with fewer adverse effects based on oriental herbal medi-
cine is an attractive research subject, and randomized controlled
trials are needed to reasonably evaluate the efﬁcacy and safety of
oriental herbal medicine for treating hypertension [8]. However,
there have been no randomized clinical trials investigating
possible effects of BOF on blood pressure (BP) proﬁles in hyper-
tensive patients with obesity.
Concerning the BP management, accumulating evidence sup-
ports that the “out-of-clinic” BP, particularly the ambulatory BP
proﬁle, is important for a proper diagnosis of hypertension and
estimation of BP control [9]. Ambulatory BP monitoring allows the
acquisition of critical information not only at the level of the 24-
h BP but also the BP variations that occur in the course of daily
activities. Among the several parameters obtained by ambulatory
BP monitoring, ambulatory BP variability reﬂects a complex phe-
nomenon that involves both short- and long-lasting changes [10].
The 24-h BP varies not only because of a reduction in BP during
nighttime sleep and an increase in the morning, but also because
of sudden, quick and short-term changes that occur both during
the day and, to a lesser extent, at night. This phenomenon,
ambulatory short-term BP variability, has been shown to depend
on sympathetic vascular modulation and on atherosclerotic
vascular changes [10]. Recently ambulatory short-term BP vari-
ability is highlighted as an emerging parameter to assess “quality
of BP control” by accumulated ﬁndings showing that hypertensive
patients with similar 24-h average BP values exhibited more se-
vere organ damage when the short-term BP variability was greater
[11e13]. Thus, short-term BP variability is associated with car-
diovascular injury and is one of important prognostic factors for
CVD [14].
In this Yokohama Combined Treatment with Oriental Herb
Randomized Efﬁcacy on Obesity Hypertension (Y-CORE) Study, we
aimed to investigate whether an integrative medicine approach
which combined an oriental medicine (BOF) and western medicine
(dietary therapy and antihypertensive drug administration) would
exerts favorable effects on the ambulatory BP proﬁle including BP
variability in hypertensive patients with obesity more efﬁciently
than the western approach alone.2. Methods
2.1. Study design
The Y-CORE study was a multicenter, prospective, randomized,
open-label, parallel-group controlled trial investigating the effects
of an integrative medicine approach on hypertensive patients with
obesity. It was conducted in accordance with the ethical principles
of the Declaration of Helsinki and was approved by the indepen-
dent ethics committee for each center. The Y-CORE study was
registered at the Clinical Trial Registry of University Hospital In-
formation Network (registration no. UMIN000003878).
2.2. Inclusion criteria
Hypertensive patients with obesity who had a history of anti-
hypertensive treatment, including diet and exercise therapies for a
period of more than 4 weeks, were eligible and recruited for the
study if they were 20e79 years of age. Obesity was deﬁned as a
body mass index (BMI) of more than 25 kg/m2. Exclusion criteria
included severe hypertension (clinic systolic BP > 180 mmHg and/
or diastolic BP > 110 mmHg), secondary hypertension, a history of
CVD including stroke in the past 6 months, uncontrolled type 1 or
type 2 diabetes (HbA1c  9.0%), women who were nursing or
pregnant, or treatment with other oriental herbal medicines.
All of the patients provided written informed consent before
participation in the study, and follow-up was undertaken by each
investigator.
2.3. Procedures
This multicenter, prospective, randomized, open-label, parallel-
group controlled trial was conducted at ﬁve hospitals in Japan, and
a central source allocated randomization using a computer-
generated, stratiﬁed, permuted block method was applied. The
block size was 4, and the stratiﬁcation factors were sex and BMI.
After the run-in period, eligible patients were randomly assigned
(in a 1:1 allocation ratio) either to the BOF add-on therapy group
(the BOF group) or the conventional control therapy group (the
control group). The core study center was located at Yokohama City
University.
In both groups, each patient received lifestyle education,
including dietary guidance by a nutritionist for obesity related
hypertension in order to restrict the energy intake according to
their pathological conditions and needs (25e30 kcal/kg-standard
body weight/day), and antihypertensive therapy was aimed at
achieving the BP goal recommended in the guideline of the Japa-
nese society of hypertension [15]. Patients in the BOF group were
initially given 2.5 g of BOF once daily; the dose of BOF was titrated
up to 7.5 g daily, as long as adverse effects appeared, during the 24-
week active treatment period. Body weight, clinic BP, ambulatory
BP, brachial-ankle pulse wave velocity (baPWV), laboratory mea-
surements, adverse events, and patient's adherence to treatment
regimens were estimated at baseline, and after 12 and 24 weeks of
treatment.
2.4. Measurements
The clinic BP was measured in a sitting position using a cali-
brated standard mercury sphygmomanometer and the recom-
mended cuff size. Two measurements were taken at 1e2 min
intervals, and their average was regarded as the clinic BP.
The ambulatory BP and heart rate (HR) were measured every
30 min with a fully automated device (TM-2431; A&D, RAC-3502;
NIHON KOHDEN, FB-270; FUKUDA DENSHI, Tokyo, Japan),
Table 1
Baseline characteristics of the study groups.
Control group BOF group p
Gender (male/female) 29/23 28/26 0.909
Age (year) 60.0 ± 12.9 59.2 ± 14.5 0.686
Height (cm) 160.9 ± 9.1 162.4 ± 8.6 0.546
Body weight (kg) 79.8 ± 17.3 82.5 ± 16.4 0.514
BMI (kg/m2) 30.6 ± 4.9 31.3 ± 5.0 0.407
Abdominal circumference (cm) 101 ± 10 105 ± 12 0.063
Clinic systolic BP (mmHg) 144 ± 20 142 ± 19 0.733
Clinic diastolic BP (mmHg) 82 ± 15 85 ± 12 0.151
Smoke (%) 16 16 0.966
Alcohol (%) 48 31 0.088
Diabetes mellitus (%) 35 23 0.194
Lipid disorder (%) 69 71 0.830
Previous cardiovascular event (%) 2 6 0.317
Fasting plasma glucose (mg/dL) 124 ± 40 112 ± 27 0.129
HbA1c (%) 6.1 ± 0.6 6.0 ± 0.6 0.212
Total cholesterol (mg/dL) 197 ± 32 203 ± 35 0.335
LDL-cholesterol (mg/dL) 113 ± 25 119 ± 31 0.309
HDL-cholesterol (mg/dL) 54 ± 15 57 ± 17 0.418
Triglycerides (mg/dL) 219 ± 213 185 ± 133 0.758
Serum creatinine (mg/dL) 0.85 ± 0.29 0.84 ± 0.31 0.810
eGFR (mL/min/1.73 m2) 68.9 ± 17.9 71.4 ± 21.9 0.750
UACR (mg/g-Cr) 189.1 ± 437.2 153.4 ± 325.0 0.283
The values are presented as means ± SD or %. BMI, body mass index; BP, blood
pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, esti-
mated glomerular ﬁltration rate; UACR, urine albumin-to-creatinine ratio.
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instructed to ﬁll out a diary to record the times of sleeping, rising
and other daytime activities. Therefore, the terms “daytime” and
“nighttime” in the present study reﬂect the average period during
which the subjects were awake/upright and asleep/supine,
respectively.
Short-term BP variability is estimated as the coefﬁcients of
variation (CV) of the BP values obtained from ambulatory BP
monitoring, and is calculated as the within-subject standard devi-
ation (SD) of all the systolic and diastolic readings divided by the
average BP during the course of the measurement period. HR
variability, which is composed of the CV of the HR values, is also
calculated as the within-subject SD of all the HR values divided by
the average HR. BP and HR artifacts during monitoring were
deﬁned according to the criteria reported in our previous studies
and were omitted from the analysis [18,19].
The baPWV values were determined with a PP analyzer (model:
BP-203RPE2; Omron Healthcare, Kyoto, Japan), as described pre-
viously [17,20]. Pulse volume waveforms were recorded with sen-
sors placed over the right brachial artery and both tibial arteries.
The baPWV values obtained by this method are reported to be
signiﬁcantly correlated with the aortic PWV determined by the
catheter method [21].
2.5. Outcomes
The primary outcome was change in the ambulatory BP proﬁle
including short-term BP variability from baseline to 24 weeks after
randomization. Changes in clinic BP, body weight, BMI, abdominal
circumference, glucose-lipid metabolism, renal function, electro-
lytes, adipokine, oxidative stress, and baPWV from baseline to 24
weeks after randomization, and adverse events during the active
treatment period were assessed as secondary outcomes.
2.6. Statistical analysis
The sample size was estimated with the following assumptions;
a was set at 0.05, power at 80%, and the intergroup difference in
changes of ambulatory short-term systolic BP variability (CV) at
1.7%. This value for the change in short-term systolic BP variability
was calculated by multiplying the body weight reduction by the
ratio of changes in short-term systolic BP variability to changes in
body weight in our previous study [16]. Assuming a 20% dropout
rate, a total sample size of n ¼ 100 randomized participants was
required.
An intention-to-treat analysis was performed, including 106 of
the 107 randomized subjects while excluding one subject who did
not meet the inclusion criteria (Supplemental Fig. 1). All of the
analyses were performed using SPSS version 19.0 (IBM Corpora-
tion). To examine the effects of BOF treatment, the change values
(absolute values after the 12 or 24 week study periods minus those
at baseline) were used for analysis. Signiﬁcant differences between
the groups were assessed by unpaired t-test or nonparametric
analysis using the Wilcoxon U test for variables that were normally
distributed. Differences between the groups for categorical vari-
ables, such as medication or past medical history, were analyzed
using the Chi-square test. Univariate and multivariate linear
regression analyses were performed to identify the factors affecting
changes in the daytime systolic BP variability. Age, gender, BOF
usage and the variables, which were signiﬁcantly associated in the
univariate analysis or were signiﬁcantly different between the
groups after treatment, were entered into the multivariate model.
The data are mean ± SD absolute values, changes from baseline at
12 and 24 weeks, or as a percentage, and a value of p < 0.05 was
considered statistically signiﬁcant.3. Results
3.1. Study population
A total of 107 hypertensive patients with obesity were screened
for eligibility from June 2010 to March 2013. At the inclusion visit,
one of them did not fulﬁll the selection criteria. 106 patients were
thus enrolled and randomly assigned (54 to the BOF group, 52 to
the control group; Supplemental Fig. 1). Of the enrolled partici-
pants, 5 patients in the control group and 8 patients in the BOF
group dropped out after the 12-week treatment and, additionally,
1 patient in the control group and 6 patients in the BOF group
dropped out after the 24 week treatment (Supplemental Fig. 1).
Therefore, the data on 93 patients for the interim evaluation and
88 patients for the ﬁnal evaluation were available for the analysis,
respectively (Supplemental Fig. 1). The baseline characteristics of
the patients are shown in Table 1. The mean age, BMI, and clinic BP
of the 106 patients were 59.6 ± 13.7 years old, 30.9 ± 5.0 kg/m2
and 143 ± 19/84 ± 13 mmHg, respectively. There were no signiﬁ-
cant differences in the baseline characteristics between the two
groups (Table 1). Medication including the antihypertensive
agents, oral glucose-lowering agents and lipid-lowering agents
used at baseline and during the whole active treatment period
were comparable in the two groups (Supplemental Table 2). The
average dose of BOF was 6.8 ± 1.4 g per day after a period of 24
weeks of treatment.3.2. Primary outcome
The effects on changes in ambulatory BP proﬁle of BOF add-on
therapy versus conventional therapy are shown in Table 2. At
baseline, there were no signiﬁcant differences in the ambulatory
average BP level and ambulatory short-term BP variability, esti-
mated as CV of the BP values obtained from ambulatory BP
monitoring, between the two groups. In accord with the study
protocol which was intended to achieve the same clinic BP goal in
each group, the ambulatory average BP decreased to comparable
levels in the two groups after a period of 24 weeks of treatment
Table 2
Comparison of ambulatory BP proﬁle in the control and BOF groups.
Baseline 12 weeks 24 weeks
After treatment Change p After treatment Change p
Ambulatory BP and HR
Daytime:
Systolic BP (mmHg)
Control group 143 ± 12 139 ± 13 4 ± 12
0.870
136 ± 13 7 ± 12
0.095
BOF group 140 ± 13 136 ± 12 4 ± 15 136 ± 11 3 ± 11
Diastolic BP (mmHg)
Control group 86 ± 8 83 ± 10 2 ± 8
0.665
82 ± 9 3 ± 7
0.045
BOF group 84 ± 10 81 ± 8 3 ± 8 82 ± 8 1 ± 6
HR (beats/min)
Control group 73 ± 9 73 ± 9 0 ± 6
0.737
72 ± 9 1 ± 6
0.119
BOF group 75 ± 11 75 ± 13 0 ± 8 74 ± 13 1 ± 9
Nighttime:
Systolic BP (mmHg)
Control group 128 ± 15 124 ± 16 3 ± 13
0.692
122 ± 14 6 ± 15
0.885
BOF group 128 ± 18 128 ± 13 2 ± 21 123 ± 15 6 ± 15
Diastolic BP (mmHg)
Control group 77 ± 10 73 ± 9 3 ± 7
0.269
72 ± 9 5 ± 8
0.195
BOF group 76 ± 10 75 ± 10 1 ± 10 72 ± 9 3 ± 7
HR (beats/min)
Control group 63 ± 8 63 ± 8 0 ± 5
0.878
63 ± 8 1 ± 6
0.430
BOF group 64 ± 12 64 ± 12 0 ± 8 63 ± 12 1 ± 6
Ambulatory BP and HR variability
Daytime:
Systolic BP variability (%)
Control group 11.5 ± 3.4 13.0 ± 4.9 1.5 ± 4.6
0.226
12.3 ± 3.1 1.0 ± 3.3
0.006
BOF group 12.2 ± 3.3 12.7 ± 4.0 0.5 ± 3.7 11.4 ± 2.8 1.0 ± 3.3
Diastolic BP variability (%)
Control group 13.8 ± 6.0 14.9 ± 6.1 1.4 ± 5.5
0.178
14.4 ± 4.5 0.9 ± 6.2
0.135
BOF group 15.4 ± 5.5 15.1 ± 5.6 0.1 ± 5.2 14.8 ± 5.9 1.1 ± 6.4
HR variability (%)
Control group 14.6 ± 6.6 13.3 ± 4.7 1.2 ± 6.9
0.946
12.4 ± 4.4 2.3 ± 7.7
0.386
BOF group 16.1 ± 6.8 14.7 ± 5.7 1.3 ± 6.9 15.7 ± 5.2 0.9 ± 6.7
Nighttime:
Systolic BP variability (%)
Control group 10.7 ± 3.5 10.6 ± 3.6 0.3 ± 4.1
0.249
10.8 ± 3.0 0.2 ± 4.6
0.885
BOF group 10.2 ± 4.0 10.5 ± 4.1 0.8 ± 4.2 10.8 ± 3.9 1.1 ± 4.7
Diastolic BP variability (%)
Control group 13.4 ± 5.3 12.5 ± 3.9 0.8 ± 4.7
0.605
12.6 ± 4.3 0.4 ± 5.6
0.199
BOF group 12.1 ± 4.3 11.5 ± 4.3 0.2 ± 5.7 13.0 ± 4.6 1.1 ± 5.5
HR variability (%)
Control group 7.7 ± 3.1 7.1 ± 3.2 0.3 ± 3.5
0.372
8.1 ± 2.7 0.6 ± 3.4
0.737
BOF group 8.1 ± 3.7 8.3 ± 3.0 0.3 ± 3.7 9.1 ± 4.9 0.9 ± 4.6
The values are presented as means ± SD. BP, blood pressure; HR, heart rate.
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vs 136 ± 11/82 ± 8 mmHg; nighttime ambulatory average BP,
122 ± 14/72 ± 9 vs 123 ± 15/72 ± 9 mmHg; Table 2). Concerning
the changes from baseline in the ambulatory average BP level by
the respective treatments, the magnitude of decrease in the day-
time diastolic BP was signiﬁcantly smaller in the BOF group than in
the control group after a period of 24 weeks of treatment (Control
vs BOF; change in daytime diastolic BP, 3 ± 7 vs 1 ± 6 mmHg,
p ¼ 0.045; Table 2).
However, with respect to the effects on changes in ambulatory
short-term BP variability of BOF add-on therapy versus conven-
tional therapy, the daytime systolic BP variability was decreased
only in the BOF group at 24 weeks and the difference was statis-
tically signiﬁcant between the BOF and control groups (Control vs
BOF; change from baseline in daytime systolic BP variability,
1.0 ± 3.3 vs1.0 ± 3.3%, p¼ 0.006; Table 2). In addition, the daytime
diastolic BP variability was similarly decreased only in the BOF
group at 24 weeks, but the difference did not reach the signiﬁcance
between the BOF and control groups (Control vs BOF; change from
baseline in daytime diastolic BP variability, 0.9 ± 6.2 vs 1.1 ± 6.4%,
p ¼ 0.135; Table 2).3.3. Secondary outcomes
As shown in Supplemental Table 3, there were no signiﬁcant
differences in the clinic BP or baPWV between the two groups at
baseline. Concerning the changes from baseline in the clinic BP or
baPWV by the respective treatments as additional efﬁcacy out-
comes, there were also no signiﬁcant differences in the changes
from baseline in the clinic BP or baPWV between the two groups
during the active treatment period (Supplemental Table 3).
Table 3 summarizes the differences in the anti-obesity effect
between groups as the additional efﬁcacy outcomes. Although each
patient received lifestyle education, including dietary guidance by a
nutritionist for obesity related hypertension in order to restrict the
energy intake according to their pathological conditions and needs
(25e30 kcal/kg-standard body weight/day) in both groups, the BOF
add-on therapy efﬁciently reduced body weight and BMI at 12 and
24weeks, and the differences were statistically signiﬁcant between
the BOF and control groups for both measures (Control vs BOF;
change from baseline in body weight, 1.2 ± 2.6 vs 2.8 ± 3.5 kg,
p ¼ 0.023; change from baseline in BMI, 0.5 ± 1.0 vs1.1 ± 1.3 kg/
m2, p ¼ 0.029; Table 3). Although abdominal circumference
exhibited a similar tendency of change at 24 weeks, the difference
Table 3
Comparison of body weight, BMI and abdominal circumference in the control and BOF groups.
Baseline 12 weeks 24 weeks
After treatment Change p After treatment Change p
Body weight (kg)
Control group 79.8 ± 17.3 78.9 ± 17.4 0.8 ± 2.5
0.007
78.3 ± 17.9 1.2 ± 2.6
0.023
BOF group 82.5 ± 16.4 80.5 ± 15.6 2.0 ± 2.7 79.6 ± 15.4 2.8 ± 3.5
BMI (kg/m2)
Control group 30.6 ± 4.9 30.1 ± 5.0 0.3 ± 0.9
0.005
29.9 ± 5.2 0.5 ± 1.0
0.029
BOF group 31.3 ± 5.0 30.3 ± 4.9 0.8 ± 1.0 30.3 ± 4.9 1.1 ± 1.3
Abdominal circumference (cm)
Control group 101 ± 10 100 ± 13 3 ± 4
0.760
100 ± 12 2 ± 6
0.053
BOF group 105 ± 12 103 ± 12 3 ± 5 102 ± 11 4 ± 6
The values are presented as means ± SD. BMI, body mass index.
Table 4
Comparison of laboratory measurements in the control and BOF groups.
Baseline 12 weeks 24 weeks
After treatment Change p After treatment Change p
Glucose-lipid metabolism:
Fasting plasma glucose (mg/dL)
Control group 124 ± 4 118 ± 31 3 ± 33
0.460
112 ± 27 9 ± 33
0.161
BOF group 112 ± 27 108 ± 25 5 ± 17 112 ± 28 1 ± 14
HbA1c (%)
Control group 6.1 ± 0.6 6.1 ± 0.6 0.0 ± 0.3
0.038
6.0 ± 0.7 0.1 ± 0.4
0.103
BOF group 6.0 ± 0.6 5.9 ± 0.6 0.1 ± 0.2 5.9 ± 0.6 0.2 ± 0.3
Total cholesterol (mg/dL)
Control group 197 ± 32 192 ± 34 4 ± 23
0.397
195 ± 31 1 ± 28
0.556
BOF group 203 ± 35 203 ± 33 1 ± 21 197 ± 32 4 ± 28
LDL-cholesterol (mg/dL)
Control group 113 ± 25 113 ± 25 0 ± 18
0.794
110 ± 24 2 ± 24
0.754
BOF group 119 ± 31 121 ± 31 2 ± 19 117 ± 27 1 ± 23
HDL-cholesterol (mg/dL)
Control group 54 ± 15 53 ± 14 0 ± 6
0.587
56 ± 15 3 ± 7
0.776
BOF group 57 ± 17 58 ± 15 1 ± 8 61 ± 17 2 ± 7
Triglycerides (mg/dL)
Control group 219 ± 213 179 ± 141 45 ± 208
0.818
193 ± 18 32 ± 214
0.399
BOF group 185 ± 133 159 ± 79 25 ± 128 137 ± 53 31 ± 78
Renal function:
Serum creatinine (mg/dL)
Control group 0.85 ± 0.29 0.84 ± 0.20 0.02 ± 0.12
0.749
0.83 ± 0.28 0.03 ± 0.13
0.920
BOF group 0.84 ± 0.31 0.81 ± 0.27 0.02 ± 0.10 0.80 ± 0.27 0.03 ± 0.12
eGFR (mL/min/1.73 m2)
Control group 68.9 ± 17.9 73.5 ± 37.1 5.2 ± 32.1
0.517
70.5 ± 19.5 2.5 ± 9.6
0.825
BOF group 71.4 ± 21.9 69.3 ± 26.6 2.7 ± 22.1 73.8 ± 24.3 2.8 ± 9.8
UACR (mg/g-Cr)
Control group 189.1 ± 437.2 138.5 ± 392.1 25.2 ± 282.5
0.896
132.0 ± 362.8 35.3 ± 312.5
0.524
BOF group 153.4 ± 325.0 159.8 ± 328.5 7.0 ± 171.5 191.2 ± 408.9 25.4 ± 209.6
Adipokine and oxidative stress:
Adiponectin (mg/mL)
Control group 3.3 ± 3.0 3.1 ± 2.2 0.0 ± 1.2
0.574
3.2 ± 2.1 0.1 ± 1.6
0.546
BOF group 3.4 ± 2.0 3.7 ± 2.1 0.1 ± 0.8 4.0 ± 2.3 0.3 ± 1.0
Resistin (ng/mL)
Control group 6.4 ± 4.8 6.2 ± 4.4 0.2 ± 2.3
0.146
5.8 ± 3.5 0.5 ± 2.5
0.015
BOF group 5.6 ± 2.4 5.9 ± 2.7 0.4 ± 1.4 5.9 ± 2.9 0.6 ± 1.5
MDA-LDL (U/I)
Control group 124 ± 35 121 ± 33 3 ± 33
0.311
119 ± 30 6 ± 37
0.044
BOF group 126 ± 51 126 ± 46 1 ± 43 129 ± 40 4 ± 43
Pentosidine (ng/mL)
Control group 24 ± 9 27 ± 10 3 ± 11
0.771
28 ± 13 5 ± 14
0.473
BOF group 30 ± 30 31 ± 19 0 ± 18 30 ± 16 2 ± 31
Urinary L-FABP (mg/g-Cr)
Control group 10.6 ± 20.4 7.2 ± 9.5 2.7 ± 20.7
0.870
7.6 ± 8.6 2.4 ± 19.5
0.682
BOF group 6.7 ± 6.4 7.6 ± 6.9 0.3 ± 5.6 9.5 ± 13.8 2.2 ± 13.0
Urinary 8-OHdG (mg/g-Cr)
Control group 4.7 ± 2.6 4.0 ± 1.9 0.6 ± 2.5
0.041
5.1 ± 3.5 0.4 ± 3.8
0.171
BOF group 4.5 ± 2.4 4.9 ± 2.3 0.3 ± 2.3 5.9 ± 3.1 1.3 ± 3.3
The values are presented as means ± SD. Dmeans the change from baseline. LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular ﬁltration
rate; UACR, urinary albumin-to-creatinine ratio; MDA-LDL, malondialdehyde-modiﬁed low-density lipoprotein; L-FABP, liver-type fatty acid binding protein; 8-OHdG, 8-
hydroxydeoxyguanosine.
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(Control vs BOF; change from baseline in abdominal
circumference, 2 ± 6 vs 4 ± 6 cm, p ¼ 0.053; Table 3).
The effects of BOF add-on therapy on glucose-lipid metabolism,
renal function, adipokine level, and oxidative stress as additional
efﬁcacy outcomes are summarized in Table 4. At baseline, there
were no signiﬁcant differences in the laboratory measurements
between the two groups. BOF add-on therapy reduced HbA1c at 12
and 24 weeks, and the change at 12 weeks from baseline in HbA1c
was statistically signiﬁcant (Control vs BOF; change from baseline
in HbA1c, 0.0 ± 0.3 vs 0.1 ± 0.2%, p ¼ 0.038; Table 4), with a non-
signiﬁcant difference in the change at 24 weeks (Control vs BOF;
change from baseline in HbA1c,0.1 ± 0.4 vs0.2 ± 0.3%, p¼ 0.103;
Table 4). However, BOF add-on therapy exerted no evident effects
on serum insulin level and HOMA-IR (data not shown). On the
other hand, BOF add on therapy did not affect the change in lipid
metabolism. Also, the renal function parameters including serum
creatinine, estimated glomerular ﬁltration rate (eGFR), and urine
albumin-to-creatinine ratio (UACR) were comparable in the two
groups during the entire active treatment period (Table 4).
With respect to adipokine and inﬂammatory markers, while
there was no signiﬁcant change in the adiponectin level between
the two groups, the resistin level was signiﬁcantly elevated in the
BOF group compared with the control group after a period of 24
weeks of treatment (Control vs BOF; change from baseline in
resistin, 0.5 ± 2.5 vs 0.6 ± 1.5 ng/mL, p ¼ 0.015; Table 4). In
addition, the BOF add on therapy signiﬁcantly increased the
malondialdehyde low-density lipoprotein (MDA-LDL) level, an
oxidative stress marker, compared with the control group after 24
week treatment (Control vs BOF; change from baseline in MDA-
LDL, 6 ± 37 vs 4 ± 43 U/I, p ¼ 0.044; Table 4). Furthermore, the
change in the urinary 8-hydroxydeoxyguanosine (8-OHdG) level in
the BOF group was signiﬁcantly higher than the control group after
a period of 12 weeks of treatment (Control vs BOF; change from
baseline in urinary 8-OHdG, 0.6 ± 2.5 vs 0.3 ± 2.3 mg/g-Cr,
p ¼ 0.041; Table 4).3.4. Exploratory analysis of contributing factors to change in
ambulatory short-term BP variability
To identify the factors affecting the beneﬁcial change in ambu-
latory BP variability, we performed multivariate linear regression
analysis. In the univariate analysis, BOF usage and the change in
serum creatinine were signiﬁcantly correlated with the change in
daytime systolic BP variability (Table 5). Thus, we entered six var-
iables, including age, sex, BOF usage, and the changes in serumTable 5
Univariate and multivariate linear regression analysis of the change in daytime
systolic BP variability.
Variables Univariate Multivariate
r p b p
Age 0.073 0.502 0.094 0.373
Sex 0.056 0.606 0.011 0.921
BOF add-on therapy group 0.296 0.006 0.298 0.008
Change in daytime systolic BP level 0.092 0.400 0.105 0.334
Change in BMI 0.088 0.424 0.062 0.572
Change in HbA1c 0.035 0.746
Change in serum creatinine 0.275 0.010 0.244 0.022
Change in resistin 0.149 0.180
Change in MDA-LDL 0.141 0.204
Change in urinary 8-OHdG 0.067 0.545
R2 ¼ 0.185
BP, blood pressure; BMI, body mass index; MDA-LDL, malondialdehyde-modiﬁed
low-density lipoprotein; 8-OHdG, 8-hydroxydeoxyguanosine.creatinine, BMI, and daytime systolic BP level, into the multivariate
analysis. The results of the multivariate linear regression analysis in
all patients indicated a signiﬁcant association between the change
in daytime systolic BP variability and the BOF usage (Table 5). In
addition, the change in serum creatinine was also signiﬁcantly
associated with the change in daytime systolic BP variability.
3.5. Tolerability
While there were no adverse events reported in the control
group, 3 patients in the BOF group experienced minor adverse
events (gastric irritation, constipation, and elevation of serum he-
patic enzyme level). No electrolyte abnormality was observed in
any of the patients during the active treatment period.
4. Discussion
This is the ﬁrst report, to the best of our knowledge, suggesting
that integrative medicine which is deﬁned as a combination ther-
apy of oriental medicine and western medicine (in this case, BOF
add-on therapy) is able to exert greater beneﬁcial effects than
conventional western therapy alone, based on “out-of-clinic”
ambulatory BP proﬁle (i.e. ambulatory BP variability) in hyperten-
sive patients with obesity (Table 2). In the present study, it was
demonstrated that the BOF add-on therapy, compared with the
conventional therapy, signiﬁcantly improved short-term BP vari-
ability on ambulatory BP monitoring (Table 2), in addition to an
anti-obesity effect (reduction in both body weight and BMI)
(Table 3). Furthermore, on multivariate analysis, BOF usage was
independently associated with the improvement in ambulatory BP
variability, in spite of there being no signiﬁcant relationship to the
changes in the BP level or BMI (Table 5). These results suggest that,
in obesity-related hypertension, BOF may exert a beneﬁcial effect
on short-term BP variability that is independent of the reductions
in body weight and/or average BP level.
Previous studies have shown that the average BP level is the
primary BP-related risk factor for CVD and an appropriate BP
reduction is essential to both prevent target organ damage and
reduce cardiovascular mortality in cases of hypertension [22]. With
respect to direct BP lowering capacity of BOF, since the medication
status of the antihypertensive agents used was comparable in the
two treatment groups during the entire treatment period and
antihypertensive agents were increased similarly in both groups to
achieve the target clinic BP level (Supplemental Table 2), the direct
effect of BOF on average BP lowering may be weak.
On the other hand, accumulating evidence has indicated that
the adverse cardiovascular consequences of high BP not only
depend on absolute BP values, but also on BP variability in the
short- and long-term [23]. Indeed, observational studies have
demonstrated that an increased short-term BP variability estimated
by ambulatory BP monitoring is closely associated with the devel-
opment, progression and severity of cardiac, vascular and renal
organ damage [12,13,24e28]. The enhanced short-term BP vari-
ability was also shown to be associated with an increased risk of
CVD and mortality independently adding to CVD risk, over and
above the contribution of elevated mean BP levels [11,29,30].
Although the relative importance of short-term BP variability on
ambulatory BP monitoring as an independent prognostic factor of
CVD and mortality is still controversial [14,31,32], a recent longi-
tudinal study reported that even small increase in short-term BP
variability is signiﬁcantly associated with enhanced risk of CVD and
mortality in 7112 hypertensive patients [33]. From these results of
accumulated evidence we would like to consider that antihyper-
tensive treatment should target improvements in short-term BP
variability on ambulatory BP monitoring, in addition to reducing
K. Azushima et al. / Atherosclerosis 240 (2015) 297e304 303absolute BP levels, in order to achieve the highest cardiovascular
protection in hypertensive patients, and BOFmay be one of possible
candidates to improve short-term BP variability in hypertension
with obesity.
With respect to the mechanism of BOF-mediated improvement
in short-term BP variability, it is widely reported that obesity is one
of the contributing factors to increased short-term BP variability
[34] and it is also reported that reduction in body weight associated
with an improvement in BP proﬁle in obese patients [35,36].
Therefore, the anti-obesity effects (reduction in body weight and
BMI) by the BOF add-on therapy may have contributed to the
improvement in ambulatory short-term BP variability in the pre-
sent study. However, in the present study there was no signiﬁcant
relationship between the reduction in BMI and the improvement in
short-term BP variability on univariate analysis (Table 5). Therefore,
it is also possible that BOF further improved the effect on short-
term BP variability, which is not mediated by its anti-obesity ef-
fect. Collectively, the BOF-mediated effect on ambulatory BP vari-
ability, rather than a direct BP lowering effect, appears to improve
the “quality” of BP management of obesity-related hypertension.
In the present study, the BOF add-on therapy accelerated the
bodyweight reduction (Table 3) and exerted amore favorable effect
on glucose metabolism than the conventional therapy group
(Table 4). These results are consistent with a previous clinical study
demonstrating that treatment with BOF was effective in decreasing
visceral fat and in improving glucose metabolism in obese Japanese
women [37]. Since BOF add-on therapy reduced HbA1c level
(Table 4) but exerted no evident effects on serum insulin level and
HOMA-IR (data not shown), further study is needed to examine
beneﬁcial effects of BOF on insulin sensitivity and related param-
eters such as leptin in obesity hypertension.
On the other hand, there were several unexpected ﬁndings
concerning the BOF-mediated changes in inﬂammatory adipokines
and markers of oxidative stress. The inﬂammatory adipokine
resistin and the oxidative stress markers MDA-LDL and urinary 8-
OHdG have been reported to be associated with cardiovascular
risk factors, including obesity and hypertension [38e41]. In the
present study, resistin, MDA-LDL, and urinary 8-OHdG in the BOF
add-on therapy group were signiﬁcantly elevated compared with
the conventional therapy group (Table 4), in spite of the efﬁcient
reduction in bodyweight and BMI in the BOF group. However, there
are several interesting preceding studies showing that the body
weight reduction exerted by dietary therapy and/or exercise guid-
ance resulted in increases in the circulating resistin concentration
and urinary 8-OHdG level [42e47]. Therefore, the causal relation-
ship between body weight reduction and changes in the inﬂam-
matory adipokines and markers of oxidative stress remains to be
determined in the pathophysiology of obesity related hypertension.
The limitations of the present study include the design not being
a double-blinded placebo-controlled study. Also, further studies
with a longer treatment period are needed to investigate whether
the beneﬁcial effects of BOF on ambulatory BP variability would be
maintained with continued beneﬁt for the cardiovascular function
parameters without serious adverse events. In addition, the R2 level
in the multivariate analysis was relatively low (R2¼ 0.185) (Table 5)
and themechanism of the beneﬁcial effect of BOF on ambulatory BP
variability remains to be determined. Since the improvement in
short-term BP variability conferred by BOF add-on therapy on
short-term BP is independent of its anti-obesity effect and BP
reduction, other factors such as its putative effects on vasoactive
substance, endothelial function and/or renal sodium handling
would be possible candidates involved [48,49]. We indeed reported
that the BOF-mediated improvement in adipose tissue function by
amelioration of adipokine dysregulation as well as the reduction of
food intake by the appetite-inhibitory property of BOF throughsuppression on the ghrelin system contribute to the BP lowering
effect and favorable metabolic modulation by BOF in a mouse
model of human metabolic disorders with obesity [7]. Neverthe-
less, as a major limitation of the present study, the mechanism
whereby BOF improved short-term BP variability is still not clear.
Therefore, further experimental results and clinical trials that
support the hypothesis and elucidate the mechanismwhereby BOF
improves short-term BP variability in hypertension with obesity.
Furthermore, the present study did not intend to examine the
effects of the individual components of BOF on BP proﬁle in the
participants. A recent case report showed that ephedrine, a
component of BOF, could induce pulmonary arterial hypertension
[50] and it would be possible that BOF treatment may exert the
adverse effects caused via the enhanced sympathetic nerve activity
by ephedrine. However, no patients in the BOF group reported
symptoms related to activation of sympathetic nerve activity, such
as palpitation, and changes in BP and HR were comparable in the
two groups after the treatment. These results suggest that the
clinical dose of BOF may not exert the adverse effects caused by
activation of sympathetic nerve due to relatively few contents of
ephedrine in BOF. Nevertheless, the target mechanism of oriental
herbal formulas at the level of each active ingredient for hyper-
tension is an important issue for the development of antihyper-
tensive drugs based on oriental herbal medicine. Therefore, further
basic and clinical studies are warranted to investigate the role of
each component of BOF in its clinical efﬁcacy.
In conclusion, the BOF add-on therapy effectively improved the
ambulatory short-term BP variability, concomitantly with its anti-
obesity effects. Therefore, the integrative medicine approach used
here, employing this oriental herbal medicine, appeared to improve
the ambulatory BP variability in obesity related hypertension better
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